Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis.

Related collections

Author and article information

Journal

Title: New England Journal of Medicine

Abbreviated Title: N Engl J Med

Publisher: Massachusetts Medical Society

ISSN (Print): 0028-4793

ISSN (Electronic): 1533-4406

Publication date Created: July 09 2020

Publication date (Print): July 09 2020

Volume: 383

Issue: 2

Pages: 141-150

Affiliations

[1 ]From the Department of Dermatology, Graduate School of Medicine, Kyoto University (K.K.), and the Departments of Clinical Development (T.M.) and Data Science (H.K.), Maruho, Kyoto, and Tokyo Women’s Medical University, Tokyo (M.K.) — all in Japan.

Article

DOI: 10.1056/NEJMoa1917006

PubMed ID: 32640132

SO-VID: 13c414c5-52b9-46f3-bd7a-f06dc9645dc1

License:

http://www.nejmgroup.org/legal/terms-of-use.htm

History

Data availability:

Comments

Comment on this article

scite_

Cited by 86

See all cited by